Eli Lilly stock soars after Q1 earnings as revenue grows 56% on strength of GLP-1 drug sales

Eli Lilly reported standout GLP-1 sales, with Zepbound revenue up 80% year over year to $4.16 billion and Mounjaro revenue up 125% to $8.66 billion. Overall revenue rose 56% to $19.7 billion, with GLP-1 drugs contributing roughly two-thirds of sales, and the FDA also approved the pill version Foundayo. Shares jumped nearly 10% on the news, though the stock remains down about 13% year to date amid competition and pricing pressure.

Analysis

The market is finally pricing Lilly less like a single-product obesity story and more like a platform with operating leverage: the key incremental insight is that each new unit of demand now has better-than-expected durability because the pill version should widen the addressable patient pool beyond injection-averse users. That matters for valuation because the stock’s de-rating this year has been driven by a “peak GLP-1 growth” narrative, and this print argues the growth curve is still early, not late.

The competitive read-through is negative for every obesity entrant that lacks either scale, convenience, or payer penetration. A pill with looser administration constraints raises the hurdle for competitors trying to win on adherence, and it should pressure smaller biotech names to either chase combination data or accept lower probability of reimbursement success. The second-order effect is manufacturing and distribution leverage: if demand remains supply-constrained, Lilly can defend premium pricing longer than the street expects, while rivals may be forced into discounting to gain share.

The contrarian risk is that the stock may have moved faster than the fundamental revision cycle. This quarter strengthens the bull case, but the next 3-6 months are likely to be about payer pushback, capacity execution, and whether the oral launch cannibalizes higher-margin injectable economics faster than it expands the market. If guidance doesn’t step up meaningfully on the next print, some of today’s multiple expansion could fade even if absolute sales keep rising.

For cross-asset positioning, the stronger signal is not just long LLY, but long LLY versus the basket of obesity hopefuls and life-science tools names that are implicitly being priced for the same demand pool. If the market starts extrapolating a multi-year GLP-1 franchise, the beneficiaries are not just the drugmaker but also select contract manufacturing and specialty distribution names with capacity bottlenecks that can command pricing power.

Key Decisions for Investors

• Add to LLY on pullbacks over the next 1-2 weeks; use strength to build, not chase, with a 3-6 month horizon and the view that the market is still underpricing the oral-expansion option value.
• Pair trade: long LLY / short a basket of smaller GLP-1 developers and obesity-exposed biotech names over 1-3 months; the risk/reward favors the incumbent with scale, payer access, and commercialization capacity.
• Buy call spreads in LLY into any post-earnings consolidation for a 3-6 month window; the setup is asymmetric if the market re-rates toward a platform multiple, but cap premium risk given the sharp move.
• Watch for signs of payer pushback or supply normalization in the next quarter; if management does not raise long-term margin or volume targets, trim exposure into the next catalyst.
• Selective long on pharma supply-chain beneficiaries with bottlenecked manufacturing exposure if oral GLP-1 adoption accelerates; the trade works best if demand growth outpaces near-term capacity.